TriSalus Life Sciences
TriSalus Life Sciences' revenue rose 53.4% to $45 million in fiscal 2025. Its operating margin was −59.7%, up from −122.9% a year earlier. Free cash flow was −$19 million. The diluted share count rose 49.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
TriSalus Life Sciences lost money in fiscal 2025: a net loss of $39 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 0 | 9 | 12 | 8 | 20 |
| Debt incl. finance leases | — | — | 0 | 22 | 33 |
| Net debt (negative means net cash) | — | — | −12 | 14 | 13 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | −36,439.0x | −3,404.7x | −11.7x | −4.9x |
| Current ratio | 0.3x | 0.5x | 1.4x | 2.0x | 2.8x |
| Quick ratio | 0.3x | 0.5x | 1.2x | 1.6x | 2.5x |
Cash flow
Projections
Project TriSalus Life Sciences' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What TriSalus Life Sciences says to expect
- Full year 2026: revenue
The Company is updating its full-year 2026 revenue guidance to $46 million to $48 million, representing growth of approximately 2% to 6% compared to full year 2025.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 5 insiders bought $3.7 million of TriSalus Life Sciences shares on the open market, and 5 insiders sold $137,130.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 18, 2026 | Mary T SzelaCEO and President, Director | Bought | 34,328 | $2.59 | $88,910 | Form 4 |
| Nov 17, 2026 | Mary T SzelaCEO and President, Director | Bought | 30,864 | $2.31 | $71,296 | Form 4 |
| Nov 17, 2026 | Gary B. GordonDirector | Bought | 10,000 | $2.20 | $22,000 | Form 4 |
| Nov 16, 2026 | Richard MarshakChief Commercial Officer | Sold | 544 | $2.43 | $1,322 | Form 4 |
| May 15, 2026 | Michael P StanskyDirector | Bought | 610,000 | $2.50 | $1.5 million | Form 4 |
| May 15, 2026 | Mats WahlstromDirector | Bought | 60,000 | $2.53 | $151,800 | Form 4 |
| May 15, 2026 | Mary T SzelaCEO and President, Director | Bought | 39,682 | $2.59 | $102,776 | Form 4 |
| May 15, 2026 | Gary B. GordonDirector | Bought | 10,000 | $2.46 | $24,600 | Form 4 |
| May 15, 2026 | David PatienceChief Financial Officer | Bought | 7,100 | $2.43 | $17,253 | Form 4 |
| May 15, 2026 | Richard MarshakChief Commercial Officer | Sold | 543 | $2.67 | $1,450 | Form 4 |
| Mar 17, 2026 | Mary T SzelaCEO and President, Director | Sold | 15,944 | $3.85 | $61,384 | Form 4 |
| Mar 16, 2026 | Jennifer StevensChief Regulatory Officer | Sold | 774 | $4.12 | $3,189 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | 4 of 9 | 3 of 9 |
| Rule of 40 | −227.1% | −81.0% | 11.5% |
| Altman Z'' | −46.85 | −45.84 | −32.29 |
| Accruals ratio | −37.7% | 44.5% | −71.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | — | Fail | Fail |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | 4 of 9 | 3 of 9 |
Compare
Put TriSalus Life Sciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| TriSalus Life Sciences | FY25 | 53.4% | −59.7% | −41.9% | — | — | 3 | |
| SANUWAVE Health | FY25 | 35.0% | 11.2% | 4.4% | — | 1.7x | — | Compare |
| Shoulder Innovations | FY25 | 49.6% | −55.6% | −76.1% | — | — | — | Compare |
| SS Innovations International | FY25 | 105.7% | −19.3% | −52.3% | — | — | — | Compare |
| KORU Medical Systems | FY25 | 22.2% | −7.2% | −1.1% | — | — | — | Compare |
5 years of figures
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | 12 | 18 | 29 | 45 |
| Revenue growth | — | — | 49.3% | 59.0% | 53.4% |
| Gross profit | — | 10 | 16 | 25 | 38 |
| Research and development | — | 21 | 30 | 18 | 15 |
| Operating income | −3 | −36 | −54 | −36 | −27 |
| Net income | 5 | −47 | −59 | −30 | −39 |
| Diluted EPS (US$) | — | −161.55 | −6.77 | −1.31 | −1.84 |
| Diluted shares (millions) | — | 0 | 9 | 25 | 38 |
| Cash flow | |||||
| Cash from operations | −2 | −32 | −51 | −41 | −18 |
| Capital expenditure | — | 1 | 1 | 0 | 1 |
| Free cash flow | — | −33 | −51 | −41 | −19 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 232 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | 0 | 1 | 5 | 9 |
| Balance sheet at fiscal year end | |||||
| Cash and short-term investments | 0 | 9 | 12 | 8 | 20 |
| Debt incl. finance leases | — | — | 0 | 22 | 33 |
| Total assets | 250 | 22 | 25 | 24 | 35 |
| Total liabilities | 17 | 34 | 52 | 50 | 69 |
| Shareholders' equity | −130 | −177 | −27 | −26 | −34 |
| Margins and ratios | |||||
| Gross margin | — | 81.8% | 85.9% | 86.1% | 84.6% |
| Operating margin | — | −293.9% | −294.3% | −122.9% | −59.7% |
| Net margin | — | −380.6% | −320.7% | −102.1% | −86.9% |
| Free cash flow margin | — | −265.9% | −276.4% | −139.9% | −41.9% |
| Rule of 40 (growth + FCF margin) | — | — | −227.1% | −81.0% | 11.5% |
| Return on capital | — | — | — | — | — |
| Return on equity | — | — | — | — | — |
| Return on assets | — | −34.6% | −254.8% | −123.7% | −132.3% |
| Net debt to EBITDA | — | — | — | — | — |